2-(phenoxycarbonyloxy)acetic acid | 565227-96-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(phenoxycarbonyloxy)acetic acid
• 英文别名: [(Phenoxycarbonyl)oxy]acetic acid；2-phenoxycarbonyloxyacetic acid
• CAS: 565227-96-5
• 化学式: C₉H₈O₅
• 分子量: 196.16
• InChiKey: YQNZKNVPFZBRQC-UHFFFAOYSA-N

物化性质

• 沸点：
  359.4±34.0 °C(Predicted)
• 密度：
  1.356±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(phenoxycarbonyloxy)acetic acid 在 sodium hydroxide 作用下， 以 水 、 乙腈 为溶剂， 生成 羟基乙酸 、 二氧化碳 、 苯酚
  参考文献：
  名称：

  苯酚的生物可逆衍生物。2. 具有类似脂肪酸结构的碳酸酯在水溶液中水解的反应性

  摘要：

  合成了一系列包含具有脂肪酸样结构的衍生物的模型苯酚碳酸酯前药，并研究了它们在 37 摄氏度下在缓冲水溶液中作为 pH 值（范围 0.4-12.5）的函数的稳定性。水溶液中的水解速率差异很大，这取决于所选的前体部分（烷基和芳基取代基）。当考虑到当前体部分的类型改变时水解机制可能改变时，例如正烷基与叔丁基，观察到的反应性差异可以通过取代基的诱导和空间性质来合理化。与由具有更长烷基链的 ω-羟基羧酸合成的衍生物相比，由于分子内催化作用，酚碳酸酯 2-(苯氧基羰基氧基)-乙酸的水解增加。与乙酸苯酯相比，碳酸酯似乎对特定酸和碱催化的水解反应较低。结果强调，期望酚碳酸酯前药可用于即用型水性制剂是不现实的。具有脂肪酸样结构的碳酸酯衍生物的稳定性，预计与血浆蛋白人血清白蛋白相互作用，证明足以进一步体外和体内评估利用 HSA 结合结合前药方法进行优化的潜力药物的药代动力学。结果强调，期望酚碳酸酯前药可用于即

  DOI：

  10.3390/12102396
• 作为产物：
  描述：

  tert-butyl 2-((phenoxycarbonyl)oxy)acetate 在 对甲苯磺酸 作用下， 以 苯 为溶剂， 生成 2-(phenoxycarbonyloxy)acetic acid
  参考文献：
  名称：

  Honkanen,E., Acta Chemica Scandinavica (1947), 1970, vol. 24, p. 1120 - 1122

  摘要：

  DOI：

文献信息

• Derivatives of 1-piperazine-and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the FAAH enzyme
  申请人：Abouabdellah Ahmed

  公开号：US20060293310A1

  公开（公告）日：2006-12-28

  The invention relates to a compound having general formula (I): Wherein m, R 1 and R 2 are as defined herein. The invention also relates to the use of the compound in therapeutics. More specifically, the compounds of the invention are inhibitors of the FAAH enzyme, and therefore, can be used for the treatment of various disorders associated with FAAH enzyme, which include in a non-limiting manner, pain, eating disorders, neurological and psychiatric pathologies, among other disorders.

  这项发明涉及具有一般式(I)的化合物：其中m，R1和R2如本文所定义。该发明还涉及该化合物在治疗中的应用。更具体地说，该发明的化合物是FAAH酶的抑制剂，因此可用于治疗与FAAH酶相关的各种疾病，包括但不限于疼痛、进食障碍、神经和精神病理等疾病。
• Arylalkylcarbamate derivatives production and use thereof in therapy
  申请人：Abouabdellah Ahmed

  公开号：US20060014830A1

  公开（公告）日：2006-01-19

  Compound of the general formula (I) in which n represents an integer ranging from 1 to 7; A is selected from the group consisting of X, Y and Z; X represents a C 1-2 -alkylene group optionally substituted by one or more C 1-12 -alkyl, C 3-7 -cycloalkyl or C 3-7 -cycloalkyl-C 1-6 -alkylene groups; Y represents a C 2 -alkenylene group optionally substituted by one or more C 1-12 -alkyl, C 3-7 -cycloalkyl or C 3-7 -cycloalkyl-C 1-6 -alkylene groups; Z represents a C 3-7 -cycloalkyl group of formula: m represents an integer ranging from 1 to 5; p and q represent integers and are defined such that p+q is a number ranging from 1 to 5; R 1 represents a hydrogen or halogen or a hydroxyl, cyano, nitro, C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -thioalkyl, C 1-4 -fluoroalkyl, C 1-4 -fluoroalkoxy or C 1-4 -fluorothioalkyl group; R 2 represents a hydrogen or halogen or a cyano, nitro, hydroxyl, C 1-4 -alkyl, C 1-4 -alkoxy, C 1-4 -thioalkyl, C 1-4 -fluoroalkyl, C 1-4 -fluoroalkoxy, C 1-4 -fluorothioalkyl group, or an aryl-type or heteroaryl-type group optionally substituted by one or more substituents; R 3 represents a group of general formula CHR 4 CONHR 5 in which R 4 represents a hydrogen or a C 1-3 -alkyl group and R 5 represents a hydrogen or a C 1-3 -alkyl, C 3-5 -cycloalkyl or C 3-7 -cycloalkyl-C 1-6 -alkylene group; in the form of the base, acid addition salt, hydrate or solvate.

  通式（I）的化合物，其中n表示从1到7的整数；A从X、Y和Z组成的组中选择；X表示一个C1-2-烷基烯基，可选地被一个或多个C1-12烷基、C3-7环烷基或C3-7环烷基-C1-6-烷基烯基取代；Y表示一个C2-烯基烷基，可选地被一个或多个C1-12烷基、C3-7环烷基或C3-7环烷基-C1-6-烷基烯基取代；Z表示一个符号为m的C3-7环烷基，其中m表示从1到5的整数；p和q表示整数，并被定义为p+q是从1到5的数字；R1表示氢或卤素或羟基、氰基、硝基、C1-4烷基、C1-4烷氧基、C1-4硫代烷基、C1-4氟代烷基、C1-4氟代烷氧基或C1-4氟代硫代烷基；R2表示氢或卤素或氰基、硝基、羟基、C1-4烷基、C1-4烷氧基、C1-4硫代烷基、C1-4氟代烷基、C1-4氟代烷氧基、C1-4氟代硫代烷基，或一个芳基或杂环芳基，可选地被一个或多个取代基取代；R3表示一个通式为CHR4CONHR5的基团，在其中R4表示氢或C1-3烷基，R5表示氢或C1-3烷基、C3-5环烷基或C3-7环烷基-C1-6-烷基烯基；以碱、酸盐、水合物或溶剂化合物的形式存在。
• ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS
  申请人：ABOUABDELLAH Ahmed

  公开号：US20070021424A1

  公开（公告）日：2007-01-25

  The invention relates to a compound of formula (I): Wherein m, n, X, Y, R 1 , R 2 , R 3 and R 4 are as defined herein. The invention also relates to the use of same in therapeutics.

  本发明涉及一种化合物，其化学式为(I)：其中m、n、X、Y、R1、R2、R3和R4如本文所定义。本发明还涉及该化合物在治疗学中的用途。
• ARYL- AND HETEROARYLPIPERIDINECARBOXYLATE-DERIVATIVES METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS
  申请人：ABOUABDELLAH Ahmed

  公开号：US20070021405A1

  公开（公告）日：2007-01-25

  The present invention comprises compounds corresponding to the general formula (I): in which m, n=1 to 3 and m+n=2 to 5; p=1 to 7; A=single bond or X, Y and/or Z; X=optionally substituted methylene; Y=C 2 -alkenylene, which is optionally substituted, or C 2 -alkynylene; Z=C 3-7 -cycloalkyl; R 1 represents a group of aryl or heteroaryl type; R 2 represents a hydrogen or fluorine atom or a hydroxyl, C 1-6 -alkoxy or NR 8 R 9 group; R 3 represents a hydrogen atom or a C 1-6 -alkyl group; R 4 represents a hydrogen atom or a C 1-6 -alkyl, C 3-7 -cycloalkyl or C 3-7 -cycloalkyl-C 1-3 -alkyl group; in the base form or in the form of an addition salt with an acid, of a hydrate or of a solvate. The compounds are useful in the treatment of a number of diseases and/or pathological conditions such as chronic pain, dizziness, vomiting, nausea, eating disorders, neurological and psychiatric pathologies, acute or chronic neurodegenerative diseases, epilepsy, sleep disorders, cardiovascular diseases, renal ischaemia, cancers, disorders of the immune system, allergic diseases, parasitic, viral or bacterial infectious diseases, inflammatory diseases, osteoporosis, eye conditions, pulmonary conditions, gastrointestinal diseases or urinary incontinence.

  本发明包括符合一般式（I）的化合物： 其中m、n = 1至3，m+n = 2至5；p = 1至7；A = 单键或X、Y和/或Z；X = 可选择取代的亚甲基；Y = 可选择取代的C2-烯基或C2-炔基；Z = C3-7-环烷基；R1表示芳香族或杂环芳族基团；R2表示氢或氟原子或羟基、C1-6-烷氧基或NR8R9基团；R3表示氢原子或C1-6-烷基基团；R4表示氢原子或C1-6-烷基、C3-7-环烷基或C3-7-环烷基-C1-3-烷基基团；以碱形式或与酸的加合盐形式、水合物形式或溶剂合物形式存在。这些化合物可用于治疗多种疾病和/或病理情况，如慢性疼痛、头晕、呕吐、恶心、进食障碍、神经和精神病理、急性或慢性神经退行性疾病、癫痫、睡眠障碍、心血管疾病、肾脏缺血、癌症、免疫系统紊乱、过敏性疾病、寄生虫、病毒或细菌感染性疾病、炎症性疾病、骨质疏松症、眼部疾病、肺部疾病、胃肠疾病或尿失禁。
• PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS
  申请人：ABOUABDELLAH Ahmed

  公开号：US20070021403A1

  公开（公告）日：2007-01-25

  The present invention comprises peridinylalkylcarbamate derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase (FAAH) enzyme inhibitors. These derivatives exert various pharmacological activities by interacting, inter alia, with cannabinoid and vanilloid receptors. By inhibiting the metabolic activity of the FAAH enzyme, compounds often responsible for the onset of a large variety of diseases and other pathological conditions are not generated and the incidence of the disease is greatly reduced.

  本发明涵盖了吡啶基烷基氨基甲酸酯衍生物，其制备方法以及将其作为脂肪酸酰胺水解酶（FAAH）酶抑制剂的治疗用途。这些衍生物通过与大麻素和辣椒素受体等相互作用，发挥各种药理活性。通过抑制FAAH酶的代谢活性，通常导致多种疾病和其他病理情况发生的化合物不会生成，疾病的发病率大大降低。